Imagion Initiates Manufacturing of Drug for Phase 2 Study
Filed with ASX · · 2 pages · English
Summary by 6ix AI
This manufacturing is a key step towards filing an Investigational New Drug application with the US FDA. The company aims to optimize the imaging agent's dose and protocol to enhance diagnostic performance during the study.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Imagion Biosystems Ltd. on 6ix
Earlier from Imagion Biosystems
- Quarterly Activities/Appendix 4C Cash Flow Report
- Successful Placement of A$3M
- Response to ASX Price Query
- Half Yearly Report and Accounts
- Variation of Convertible Securities Agreement
Later from Imagion Biosystems
- Appendix 4E and 2024 Financial Report
- Appendix 4C and Quarterly Activities Report - March 2025
- Imagion Receive Positive FDA Feedback for HER2 Phase 2 Trial
- Imagion MagSense Breast Cancer Program Phase 2 Trial Update
- Appendix 4C and Quarterly Activities Report - June 2025
Follow Imagion Biosystems into a list and get an email when it puts out news.
Follow Imagion Biosystems